再生元制药(REGN)公布1/2期临床试验积极数据,股价回撤后迎来利好

· gurufocus.com

2026年10月1日,再生元制药公司(纳斯达克:REGN)公布了靶向低级别浆液性卵巢癌的双特异性T细胞衔接器ubamatamab的1/2期临床试验初步结果。

On October 01, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced initial results from its Phase 1/2 clinical trial of ubamatamab targeting low-grade ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI